In the News
Basal insulin does not contribute to emotional distress in type 2 diabetes, study finds
A randomized trial found no evidence that basal insulin affected emotional distress and indicated that insulin glargine and liraglutide were associated with a modest decrease in diabetes-related distress at one year.
Real-time and intermittently scanned CGM associated with improved glycemic control in type 2 diabetes
A meta-analysis of 12 trials found that continuous glucose monitoring (CGM) resulted in an average difference in HbA1c of −0.31% versus self-monitoring, with a trend toward a larger effect with real-time monitoring.
Position statement calls for prioritizing patients' experience in diabetes care
The Endocrine Society's recommendations are based on roundtable meetings with representatives from governmental and other organizations, patient advocacy groups, and professional societies, including ACP.
MKSAP Quiz: Evaluation in the ICU for urosepsis
A 70-year-old woman is evaluated in the ICU after admission for urosepsis. Appropriate antibiotics and intravenous fluids were initiated. She remains critically ill and continues to have poor oral intake. She has type 2 diabetes mellitus, which has been previously well controlled. Following lab tests, what is the most appropriate treatment?
Spotlight on NAFLD
Recent studies looked at the risks associated with nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD), the effects of diabetes drugs on the condition, and whether machine learning can help identify patients at risk.
Bariatric surgery improves long-term diabetes outcomes more than medication, lifestyle interventions
Patients who underwent bariatric surgery for type 2 diabetes had remission rates of 18.2% at seven years and 12.7% at 12 years, compared to 6.2% and 0%, respectively, in patients treated with medical and lifestyle interventions, a new review found.
First over-the-counter CGM cleared for marketing
The integrated continuous glucose monitor (CGM) is intended for anyone ages 18 years and older who does not use insulin.
FDA warns about smartwatches, rings to measure glucose
Smartwatches and smart rings that claim to measure blood glucose levels without piercing the skin are being sold commercially, but none have been approved by the FDA, the agency warned.